tst001
mAbexperimental
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started May 28, 2020 (NCT04396821)
Timeline
Indications
Mechanism of action
- Claudin-18INHIBITOR
CLDN18 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06093425 | Phase 3 | Oct 31, 2023 | Transcenta Therapeutics |
| NCT05608785 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2023 | Henan Medical University |
| NCT05190575 | Phase 2 | Jan 14, 2022 | Fudan University |
| NCT04495296 | Phase 1 | Aug 13, 2020 | Chinese Academy of Medical Sciences, Fudan University, Henan Medical University, Mabspace Biosciences, Zhejiang University |
| NCT04396821 | Early Phase 1 (Phase 1) | May 28, 2020 | Mabspace Biosciences, NEXT Oncology |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fudan University | Academic/Hospital | 2 | 1 | 2 | 2020 |
| Henan Medical University | Academic/Hospital | 2 | 1 | 2 | 2020 |
| Mabspace Biosciences | For profit | 2 | 2 | 1 | 2020 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2020 |
| NEXT Oncology | For profit | 1 | 0 | 1 | 2020 |
| Transcenta Therapeutics | For profit | 1 | 1 | 1 | 2023 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2020 |
7 organizations
Page 1 / 1